Neurocrine Biosciences (NBIX) is trading lower today as the market continues to recalibrate expectations around the company’s 2026 outlook for INGREZZA, its core growth driver. Neurocrine guided 2026 INGREZZA net product sales to $2.7–$2.8 billion, which investors have treated as a sign that growth could normalize versus prior periods rather than re-accelerate. (sec.gov)

The stock’s down move reflects sentiment that the midpoint of the 2026 range doesn’t leave much room for upside if volumes or net pricing underwhelm, particularly after a string of post-earnings model resets. In recent weeks, multiple firms have published target-price reductions and at least one notable downgrade has circulated around the name, reinforcing a cautious tone even as the long-term thesis remains intact for many holders. (streetinsider.com)

Key swing factors for NBIX over the coming weeks include: (1) any incremental commentary that changes how investors model INGREZZA volume growth versus net price headwinds, (2) updates on the company’s broader portfolio performance, and (3) whether fresh analyst notes emerge that either validate the conservative guidance framework or argue that expectations have been reset too far. (fool.com)